Minnesota House Advances Psilocybin Therapy Bill in Bipartisan Mental Health Push

Minnesota lawmakers took a decisive step toward expanding mental health treatment options Monday, advancing legislation that would legalize psilocybin-assisted therapy for adults struggling with depression, PTSD, substance use disorder, and chronic pain.

The House Health Finance and Policy Committee approved HF 2906 in a voice vote, sending the bill to the Commerce Finance and Policy Committee for further review. If enacted, Minnesota would join Oregon and Colorado in creating state-regulated frameworks for psychedelic therapy — though the North Star State's approach includes novel safeguards that distinguish it from West Coast models.

A Pilot Program with Built-In Constraints

Unlike broader legalization efforts elsewhere, Minnesota's proposal launches as a carefully bounded pilot. The Department of Health and Office of Cannabis Management would license just 20 to 50 facilitators initially, cap patient enrollment at 1,000 for the first three years, and require at least three approved psilocybin testing facilities to ensure quality control.

Rep. Andy Smith (DFL), the bill's sponsor, framed the legislation as responsive to recommendations from a state psychedelics task force established under separate law. "Mental illness is one of the defining issues in our society today," Smith told committee members. "We are talking about a new tool — a therapeutic psilocybin program here in Minnesota that has great potential."

The three-phase treatment model mirrors clinical trial protocols: preparation sessions where patients consult with registered facilitators, administration in supervised settings (either licensed facilities or approved private residences), and integration work to help patients process therapeutic experiences. No unsupervised use. No recreational pathway.

Bipartisan Support Amid National Psychedelic Momentum

The legislation's bipartisan backing stands out in an otherwise divided Minnesota legislature. Rep. Nolan West (R), a co-sponsor, preemptively addressed skepticism that the bill represents "the nose under the camel's tent for legalization."

"This is a pilot program," West emphasized, distinguishing the medical framework from cannabis liberalization debates. He also pointed to growing federal interest in psychedelics, noting that HHS Secretary Robert F. Kennedy Jr. and other Trump administration officials have publicly discussed expanding access to these therapies.

That shift at the federal level — where psychedelics remain Schedule I substances under the Controlled Substances Act — has emboldened state-level experimentation. Minnesota's bill would reschedule psilocybin from Schedule I to Schedule IV under state statute, reflecting a lower abuse potential and reduced dependency risk.

Funding Questions Could Delay Implementation

While political resistance appears minimal, Smith acknowledged that funding challenges may prevent enactment this session. The bill doesn't yet identify a dedicated revenue stream for program oversight, facilitator training, or laboratory certification.

"If it doesn't happen this year, I feel very confident in the next budget year that we'll be able to get this done," Smith told the Star Tribune.

Kurtis Hanna, board president of the Psychedelic Access Project, called the committee vote "encouraging" given Minnesota's polarized political climate. "Veterans, mental health practitioners, doctors and patients came out in full force today to support providing another tool in the toolbox to Minnesotans suffering from mental health issues," Hanna said.

Why Psilocybin? The Clinical Evidence Gap

Proponents point to emerging research showing psilocybin's promise for treatment-resistant depression, end-of-life anxiety, and substance use disorders. Recent studies from Johns Hopkins, NYU, and Imperial College London have documented significant symptom reductions in patients who failed to respond to conventional therapies.

But the evidence base remains thinner than for FDA-approved medications. The agency rejected MDMA-assisted therapy for PTSD last year after trial design concerns emerged, underscoring regulatory skepticism about psychedelic medicine's rigor.

Minnesota's structured approach — with mandatory facilitator licensing, state oversight, and patient caps — appears designed to generate the kind of real-world data that could inform broader policy decisions. The Psychedelic Medicine Advisory Committee created under the bill would collaborate with the Health Commissioner on program rules, creating a feedback loop between clinical practice and regulation.

What Happens Next

The bill faces at least one more committee stop before reaching the full House floor. If it clears the House, it would need Senate approval and Governor Tim Walz's signature. Walz, a Democrat who signed cannabis legalization into law in 2023, has not publicly weighed in on the psilocybin proposal.

Implementation timelines remain unclear even if the bill passes. Oregon's Measure 109, approved by voters in 2020, didn't launch its first licensed services until 2023 — a three-year gap spent developing training curricula, lab standards, and regulatory frameworks.

Minnesota's phased rollout with tight patient caps suggests officials are learning from Oregon's rocky start, when high costs ($3,500+ per treatment cycle) and limited geographic access constrained uptake. By starting small and requiring both licensed facilities and private residence options, Minnesota aims to balance safety with accessibility.

The legislation also imposes penalties for unauthorized psilocybin cultivation or administration outside program parameters, ensuring the therapeutic pathway doesn't become a de facto legalization loophole.

Broader Context: States Moving Ahead of Federal Action

Minnesota's bill adds momentum to a growing patchwork of state psychedelic reforms. Beyond Oregon and Colorado's therapeutic programs, cities including Seattle, Detroit, and Washington DC have decriminalized personal possession of psilocybin mushrooms. Massachusetts voters will decide on a similar measure in 2024.

At the federal level, the VA has launched trials exploring MDMA and psilocybin for veterans with PTSD and depression, though Congress has yet to advance comprehensive rescheduling legislation.

The disconnect between state-level enthusiasm and federal prohibition creates legal gray zones. Facilitators in Minnesota's proposed program would still technically violate the Controlled Substances Act, though DOJ enforcement guidance under recent administrations has deprioritized prosecution of state-legal psychedelic therapy.

For now, Minnesota lawmakers are betting that carefully regulated pilot programs will generate evidence compelling enough to shift federal policy — or at least provide political cover for inaction at the DEA.

Whether that strategy succeeds may depend on how the next 1,000 Minnesota patients fare.